-

05:25:34 PM

MRNA Stock News

MRNA - Moderna Inc

03/22/23 2:00 AM

Nasdaq : MRNA

management

BenevolentAI Strengthens its Board of Directors with the Appointment of Digital Innovation Expert Marcello Damiani

BenevolentAI, a leading, clinical-stage AI-enabled drug discovery and development company, today announces the appointment of Marcello Damiani to its Board of Directors. Drawing from his senior executive leadership experience at global organisations such as Moderna and bioMérieux, Marcello offers a unique perspective and understanding of...

RHEA-AI

neutral

03/14/23 5:40 PM

Nasdaq : MRNA

clinical trial

Moderna Announces Phase 2 Data on mRNA-4157/V940, an Investigational mRNA Personalized Cancer Vaccine, to be Presented at the 2023 AACR Annual Meeting

Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that two abstracts on mRNA-4157/V940 an investigational mRNA personalized cancer vaccine, have been accepted for presentation

RHEA-AI

neutral

03/10/23 11:00 AM

Nasdaq : MRNA

Moderna Outlines Commitment to Corporate Growth and Announces U.S. Expansion in 2023

Expansion includes new West Coast offices in South San Francisco, California and Seattle, Washington New offices complement existing locations in Cambridge, MA; Norwood, MA; Atlanta, GA; Bethesda, MD; and Princeton, NJ Moderna currently has offices in 17 locations worldwide Company plans to hire

RHEA-AI

very positive

02/28/23 7:30 AM

Nasdaq : MRNA

conferences

Moderna to Present at Cowen's 43rd Annual Health Care Conference

Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced its participation in a fireside chat at Cowen's 43rd Annual Health Care Conference on Monday, March 6 th at 9:10 a.m. ET.

RHEA-AI

neutral

02/23/23 7:00 AM

Nasdaq : MRNA

earnings

Moderna Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Updates

Fourth quarter 2022 revenues of $5.1 billion; GAAP net income of $1.5 billion and GAAP diluted EPS of $3.61 Full-year 2022 revenues of $19.3 billion; GAAP net income of $8.4 billion and GAAP diluted EPS of $20.12 Company reiterating approximately $5 billion in COVID-19 sales contracted for delivery

RHEA-AI

positive

02/22/23 4:05 PM

Nasdaq, NYSE : MRNA, MRK

Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination With KEYTRUDA(R) (pembrolizumab), was Granted Breakthrough Therapy Designation by the FDA for Adjuvant Treatment of Patients With High-Risk Melanoma Following Complete Resection

Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Merck (NYSE:MRK), known as MSD

RHEA-AI

very positive

02/22/23 7:00 AM

Nasdaq : MRNA

Moderna And Life Edit Therapeutics Enter Strategic Collaboration to Accelerate the Development of Novel In Vivo Gene Editing Therapies

Collaboration to combine Moderna's mRNA platform with Life Edit's proprietary gene editing technologies, including base editing capabilities Multi-target collaboration to advance potentially life-transformative or curative therapies for some of the most challenging genetic diseases Life Edit to

RHEA-AI

positive

02/17/23 11:00 AM

Nasdaq : MRNA

covid-19

Health Canada Authorizes Moderna's Omicron-Targeting Bivalent COVID-19 Vaccine in Children & Adolescents (6-17 Years)

The recommendation is based on clinical data for Moderna's bivalent Omicron-targeting COVID-19 vaccine, mRNA.1273.214 Moderna's bivalent Omicron-targeting COVID-19 vaccines (mRNA.1273.214 (BA.1) & mRNA.1273.222 (BA.4/5)) are currently authorized for use in individuals 18 years of age and older in

RHEA-AI

neutral

02/16/23 4:05 PM

Nasdaq : MRNA

clinical trial

Moderna Announces Interim Phase 3 Safety and Immunogenicity Results for mRNA-1010, a Seasonal Influenza Vaccine Candidate

mRNA-1010 demonstrated superiority on seroconversion rates for A/H3N2 and A/H1N1, superiority on geometric mean titer ratios for A/H3N2, and non-inferiority on geometric mean titer ratios for A/H1N1 Non-inferiority was not met for seroconversion rates and geometric mean titer ratios for the

RHEA-AI

neutral

02/03/23 8:45 AM

Nasdaq : PSNL, MRNA

clinical trial

Personalis and Moderna Sign New Agreement to Leverage NeXT Platform™ in Personalized mRNA Cancer Vaccine Clinical Trials

Personalis, Inc., a leader in advanced genomics for precision oncology, and Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, today announced the companies have signed a new agreement to continue using the Personalis NeXT Platform ® as part of upcoming clinical studies evaluating mRNA-4157/V940, an...

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 10 Next